Avidity Biosciences (NASDAQ:RNA) is a biotech company focused on developing a new class of RNA-based therapies to treat a range of diseases with an unmet medical need, including muscular dystrophy, myotonic dystrophy, and other muscle-related disorders. Avidity's main projects revolve around its proprietary technology platform that enables the targeted delivery of oligonucleotides directly to specific tissues, such as muscles or heart, aiming to overcome one of the major limitations of current RNA therapies. The company’s objectives are to advance these innovative treatments through clinical trials, demonstrating their safety and efficacy, while seeking partnerships and collaborations to accelerate their development and potential commercialization.